micro-community-banner
  • Saved

1yr

Did you know? Recent studies show that the prevalence of allergies has increased dramatically, with food allergies affecting about 8% of children in the U.S. This rising trend may be linked to environmental changes and lifestyle factors, including increased urbanization and dietary changes, highlighting the need for more comprehensive strategies to manage and prevent allergic conditions.

What strategies can healthcare systems adopt to address the growing prevalence of allergies in children and improve their long-term health outcomes?

background

What strategies can healthcare systems adopt to address the growing prevalence of allergies in children and improve their long-term health outcomes?

  • Saved

1yr
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) will host its annual meeting at the Savannah Convention Center and Westin Savannah Harbor in Georgia from Oct. 15 to 18, 2024.

The meeting will focus on improving patient care, medical knowledge, interpersonal communication, professionalism, and systems-based practices in neuromuscular and musculoskeletal disorders; genomics and emerging gene therapies; new technologies and treatments; autoimmune disorders; neuropathies, antibody testing, ultrasound, electrodiagnosis, and biopsy skills.

  • Saved

1yr
Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis - PubMed

Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39318549/

Myasthenia Gravis (MG) is a chronic autoimmune disease that primarily affects the neuromuscular junction, leading to muscle weakness in patients with this condition. Previous studies have identified several dysfunctions in...

Noncoding RNAs, including miRNA, lncRNA, and circRNA, are key regulators in myasthenia gravis, impacting thymus and PBMC dysfunctions, with potential as biomarkers for diagnosis and therapeutic targets.

  • Saved

1yr
A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis - PubMed

A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38726639/

Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase...

Telitacicept showed safety, tolerability, and clinical efficacy in reducing disease severity in patients with generalized myasthenia gravis, with significant improvements in QMG scores over 24 weeks.

  • Saved

1yr
Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review - PubMed

Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39202282/

Immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment, but their use is linked to immune-related adverse events (irAEs), including the rare ICI-associated myocarditis, myositis, and myasthenia gravis (MMM) overlap...

MMM overlap syndrome, a rare but severe complication of immune checkpoint inhibitors, requires urgent recognition and corticosteroid treatment due to high mortality, especially in cancer patients receiving ICIs.